妊娠期持续使用抗肿瘤坏死因子α:母亲可能出现并发症而胎儿不受影响——基于法国国家医疗保险数据库的回顾性队列研究(EVASION)
该研究基于法国国家医疗保险数据库SNIIRAM开展暴露/非暴露回顾性队列,纳入2011至2014年妊娠的炎症性肠病女性,评估妊娠期抗肿瘤坏死因子α(anti-TNFα)暴露的安全性。结果显示,调整混杂因素后,抗肿瘤坏死因子α暴露与母亲总体并发症风险升高相关(aOR=1.49;95%CI:1.31-1.67)和感染风险升高相关(aOR=1.31;95%CI:1.16-1.47),但子代出生后第一年感染风险未升高(aOR=0.89;95%CI:0.76-1.05)。妊娠24周后继续使用抗肿瘤坏死因子α未增加母亲并发症风险,但中断治疗会增加疾病复发风险。
要点
- 妊娠期抗肿瘤坏死因子α暴露与母亲总体并发症风险升高相关(aOR=1.49;95%CI:1.31-1.67)。
- 妊娠期抗肿瘤坏死因子α暴露与母亲感染风险升高相关(aOR=1.31;95%CI:1.16-1.47)。
- 子代出生后第一年感染风险未升高(aOR=0.89;95%CI:0.76-1.05);妊娠24周后继续用药未增加母亲并发症风险,但中断治疗会增加疾病复发风险。
核心结论
- 与未暴露者相比,妊娠期抗肿瘤坏死因子α治疗增加母亲并发症风险;但妊娠24周前中断治疗会增加疾病复发风险。
- 暴露于抗肿瘤坏死因子α的子代至出生后1岁未见感染风险增加。
研究设计与样本
- 在法国国家医疗保险数据库SNIIRAM上开展暴露/非暴露回顾性队列研究(EVASION)。
- 纳入2011至2014年间妊娠的所有炎症性肠病女性,排除可能因合并疾病接受抗肿瘤坏死因子α治疗的女性。
- 从SNIIRAM处方数据库检索妊娠期抗肿瘤坏死因子α暴露(英夫利西单抗、阿达木单抗、戈利木单抗或培塞利珠单抗)。
- 共分析11,275次妊娠(8726例炎症性肠病女性),其中1457次(12.9%)妊娠暴露于抗肿瘤坏死因子α,主要为英夫利西单抗或阿达木单抗。
- 暴露者中,1313/7722(17.0%)为克罗恩病,144/3553(4.1%)为溃疡性结肠炎。
主要发现
- 调整疾病严重程度、激素使用、年龄、炎症性肠病类型、病程及合并使用6-巯基嘌呤后,抗肿瘤坏死因子α治疗与母亲总体并发症风险升高相关(aOR=1.49;95%CI:1.31-1.67)。
- 抗肿瘤坏死因子α治疗与母亲感染风险升高相关(aOR=1.31;95%CI:1.16-1.47)。
- 妊娠24周后继续使用抗肿瘤坏死因子α未增加母亲并发症风险,但中断抗肿瘤坏死因子α会增加疾病复发风险。
- 妊娠期暴露于抗肿瘤坏死因子α的母亲所生子代未发现感染风险增加(aOR=0.89;95%CI:0.76-1.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Inflammatory bowel diseases (IBD) need long-term treatment, which can influence pregnancies in young women. Uncontrolled IBD is associated with poor pregnancy outcomes. Despite the labeling of Anti-tumor necrosis factor (TNF) antibodies (anti-TNFα) which indicates that their use is not recommended during pregnancy, anti-TNFα are increasingly being used during pregnancy and may expose women and their fetuses to treatment-related complications. Existing recommendations on the timing of treatment during pregnancy are inconsistent. We aimed to assess the safety of anti-TNFα treatment in pregnant women with IBD, and up to the first year of life for their children. METHODS: An exposed/non exposed retrospective cohort was conducted on the French national health system database SNIIRAM (Système National d'Information Inter-Régimes de l'Assurance Maladie). All IBD women who became pregnant between 2011 and 2014 were included. Women with concomitant diseases potentially treated with anti-TNFα were excluded. Anti-TNFα exposure (infliximab, adalimumab, golimumab or certolizumab pegol) during pregnancy was retrieved from the exhaustive prescription database in SNIIRAM. The main judgment criterion was a composite outcome of disease-, treatment- and pregnancy-related complications during pregnancy for the mother, and infections during the first year of life for children. RESULTS: We analyzed data from 11,275 pregnancies (8726 women with IBD), among which 1457 (12.9%) pregnancies were exposed to anti-TNFα, mainly infliximab or adalimumab, with 1313/7722 (17.0%) suffering from Crohn's disease and 144/3553 (4.1%) from ulcerative colitis. After adjusting for disease severity, steroid use, age, IBD type, and duration and concomitant 6-mercaptopurine use, anti-TNFα treatment was associated with a higher risk of overall maternal complications (adjusted Odds Ratio (aOR) = 1.49; 95% confidence interval (CI): 1.31-1.67) and infections (aOR = 1.31; 95% CI: 1.16-1.47). Maintaining anti-TNFα after 24 weeks did not increase the risk of maternal complication, but interrupting the anti-TNFα increased relapse risk. No increased risk for infection was found in children (aOR = 0.89; 95% CI: 0.76-1.05) born to mother exposed to anti-TNFα during pregnancy. CONCLUSIONS: Anti-TNFα treatment during pregnancy increased the risk of maternal complications compared to unexposed; however, discontinuation before week 24 increased the risk of disease flare. There was no increased risk for children exposed to anti-TNFα up to 1 year of life.
引用
- Luu M, Benzenine E, Doret M, et al. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol. 2018. PMID: 29961771. doi:10.1038/s41395-018-0176-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。